International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

The guideline from the International Society for the Study of Women's Sexual Health provided a framework for using systemic testosterone to treat hypoactive sexual desire disorder (HSDD) in women, particularly postmenopausal women. It recommended transdermal testosterone therapy, emphasizing informed consent and shared decision-making, while noting the lack of long-term safety data and regulatory challenges, as no government-approved products were available in the U.S. except in Australia. The guideline highlighted the importance of maintaining testosterone within premenopausal levels to avoid androgenic side effects and advised against using compounded products due to insufficient data. It also stressed a biopsychosocial approach, incorporating both pharmacologic and non-pharmacologic options, and called for further research to establish long-term safety and efficacy.